Alta Life Sciences
Alta Life Sciences is a venture capital investment firm founded in 2016 and based in Barcelona, Spain. The firm specializes in investing across all stages of development, from seed financing to commercial growth, focusing on companies within the life sciences sector. Its investment portfolio includes a diverse range of areas such as biotechnology, medical devices, diagnostics, genomics, and digital health. By targeting both early-stage and later-stage companies, Alta Life Sciences aims to support innovative ventures that contribute to advancements in healthcare and technology.
Past deals in Barcelona
INBRAIN Neuroelectronics
Series A in 2021
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.
INBRAIN Neuroelectronics
Seed Round in 2020
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.